Rigel Pharmaceuticals (NASDAQ: RIGL) on Tuesday, plunged -4.14% from the previous trading day, before settling in for the closing price of $17.15. Within the past 52 weeks, RIGL’s price has moved between $7.48 and $29.82.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 26.32% over the past five years. The company achieved an average annual earnings per share of 120.53%. With a float of $17.27 million, this company’s outstanding shares have now reached $17.61 million.
Let’s look at the performance matrix of the company that is accounted for 147 employees. In terms of profitability, gross margin is 89.43%, operating margin of 6.03%, and the pretax margin is 2.46%.
Rigel Pharmaceuticals (RIGL) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Rigel Pharmaceuticals is 1.98%, while institutional ownership is 67.84%. The most recent insider transaction that took place on Feb 05 ’24, was worth 10,167. In this transaction EVP, Chief Commercial Officer of this company sold 8,918 shares at a rate of $1.14, taking the stock ownership to the 349,093 shares. Before that another transaction happened on Feb 02 ’24, when Company’s EVP, Chief Commercial Officer sold 5,601 for $1.13, making the entire transaction worth $6,329. This insider now owns 358,011 shares in total.
Rigel Pharmaceuticals (RIGL) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 120.53% per share during the next fiscal year.
Rigel Pharmaceuticals (NASDAQ: RIGL) Trading Performance Indicators
Rigel Pharmaceuticals (RIGL) is currently performing well based on its current performance indicators. A quick ratio of 1.81 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.84. Likewise, its price to free cash flow for the trailing twelve months is 27.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.22, a number that is poised to hit 0.30 in the next quarter and is forecasted to reach 0.98 in one year’s time.
Technical Analysis of Rigel Pharmaceuticals (RIGL)
Rigel Pharmaceuticals (NASDAQ: RIGL) saw its 5-day average volume 0.26 million, a positive change from its year-to-date volume of 0.17 million. As of the previous 9 days, the stock’s Stochastic %D was 19.15%. Additionally, its Average True Range was 1.61.
During the past 100 days, Rigel Pharmaceuticals’s (RIGL) raw stochastic average was set at 36.92%, which indicates a significant increase from 14.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.74% in the past 14 days, which was lower than the 91.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.07, while its 200-day Moving Average is $13.78. Nevertheless, the first resistance level for the watch stands at $17.30 in the near term. At $18.15, the stock is likely to face the second major resistance level. The third major resistance level sits at $19.49. If the price goes on to break the first support level at $15.11, it is likely to go to the next support level at $13.77. Assuming the price breaks the second support level, the third support level stands at $12.92.
Rigel Pharmaceuticals (NASDAQ: RIGL) Key Stats
Market capitalization of the company is 289.59 million based on 17,615K outstanding shares. Right now, sales total 116,880 K and income totals -25,090 K. The company made 55,310 K in profit during its latest quarter, and 12,420 K in sales during its previous quarter.
